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Objectives: Alzheimer’s disease (AD) afflicts up to 9% of people aged 65 and over 
worldwide, with prevalence projected to increase. AD is associated with reduced 
quality of life and high treatment and management costs. A number of recently 
developed screening and preventative interventions offer reduction in resource use 
and improvement in quality of life for AD patients. The majority of existing models 
for economic evaluation of AD interventions focus on pharmaceuticals and due 
to their limited scope and time-horizon are unsuitable for evaluation of screening 
and preventative strategies. It is proposed to develop a decision model to ascertain 
the most cost-effective ‘mix’ of preventative and screening methods for Denmark. 
The objective of this study is to develop and validate such a model for economic 
evaluation of non-pharmaceutical interventions for AD MethOds: A Markov model 
was developed, representing transitions of a hypothetical cohort of 65 year olds 
from ‘no AD’ to different stages of AD (Very Mild through to Severe). AD could either 
be ‘identified’ or ‘not identified’ to reflect the difference in costs associated with 
treatment and management. Due to absence of Danish data, the model utilised 
transition probabilities based on US data; AD-associated costs and utilities were 
obtained from Danish and Swedish data, respectively. The model was externally vali-
dated against an epidemiological study of AD in Denmark to predict prevalence and 
stage of AD by age. Results: The model accurately predicted Danish age-specific 
prevalence of AD, although the prevalence for the 75-79 age group was overesti-
mated by 3%. The model also produced accurate predictions of the distribution of 
AD severity. cOnclusiOns: The model provides a simple and robust framework 
for economic evaluation of screening and other non-pharmaceutical interventions 
for AD. The lack of up to date epidemiological data on AD is a challenge for model 
validation and introduces uncertainty.
PRM74
ContRasting Model PRediCted life exPeCtanCy in Patients With 
tyPe 2 diabetes aCRoss diffeRent MoRtality Risk PRediCtion Models 
VeRsus data fRoM the Canadian ChRoniC disease suRVeillanCe 
systeM
McEwan P1, Foos V2, Lamotte M3
1Health Economics and Outcomes Research Ltd, Monmouth, UK, 2IMS Health, Basel, Switzerland, 
3IMS Health, Vilvoorde, Belgium
Objectives: Diabetes is known to be associated with a considerable decline in life 
expectancy (LE). The aim of this study was to use a modelling approach to assess 
LE in low, intermediate and high-risk type-2-diabetes (T2D) populations and to 
compare these to observations from the Canadian-Chronic-Disease-Surveillance-
System (CCDSS). MethOds: This study used the IMS-Core-Diabetes-Model (CDM), 
a validated diabetes simulation model, to project the LE of T2D individuals with a 
low-risk (age= 55, diabetes duration= 5, no CVD history), intermediate-risk (age= 65, 
diabetes duration= 15, moderate CVD history) and high-risk profile (age= 80, diabetes 
duration= 30, advanced CVD history). LE was predicted utilising three alternative 
mortality risk prediction models (RPMs) from the UKPDS 68 study (UK68), the UKPDS 
82 study (UK82) and a risk equation based on Western Australia (WA) administrative 
data. Life-years-lost (LYL) in diabetes vs. no-diabetes populations was estimated 
based on the difference in age matching LE obtained from UK-national-life-tables 
subtracted by CDM projected-LE. Results were finally contrasted to LE and LYL esti-
mations from the CCDSS study. Results: When UK68 mortality RPMs were applied, 
LE projected was 23.29, 15.94 and 7.78 years for the low, intermediate and high risk 
cohort. This compared to 22.16, 14.88 and 7.29 years utilising UK82 RPMs and 25.94, 
18.11 and 9.05years when utilising the WA RPMs. Based on UK life table data, LYL in 
diabetes vs. no-diabetes populations were 4.76, 3.61 and 1.11 (UK68), 5.89, 4.67 and 
1.60 (UK82) and 2.11, 1.44 and -0.15 (WA) years. The CCDSS study reported outcomes 
for the low risk (age 55) and high risk (age 80) profile at 24.5 and 8.3 years (LE) and 5.5 
and 2.25 years (LYL), respectively. cOnclusiOns: UKPDS based models predicted 
LE and LYL very closely to CCDSS study findings. The Western Australian RPM seems 
not to be applicable to a UK and Canadian population.
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Objectives: Cost-effectiveness (CE) is increasingly used for resource allocation 
worldwide. One key hurdle for its widespread use is the lack of a widely accepted 
methodology to derive thresholds at the healthcare system (HS) or country level. 
The objective is to propose a methodology and derive local CE thresholds based 
on per capita health expenditures (pcHE) and life expectancy (LE). MethOds: 
Our approach is based on the relationship between pcHE and LE; assuming that 
the increase in expenditures reflects the CE of the interventions added to reach 
current LE. For HS willing to maintain or increase their secular trend of raising 
pcHE in order to improve health, the threshold (measured in units of pcHE) will 
be: Threshold= (LE+1)*i-LE; where LE is measured in life-years (LY) or QALYs; and 
“i” is the ratio of increase in pcHE that the HS is willing to accept to increase LE 
by one unit (eg i= 1.09 for a 9% increase). For HS with cost-containment man-
dates: Threshold= LE-((LE-1)/i), where “i” represents the past increase in pcHE to 
gain the last unit of LE. We used OLS to predict “i” for 185 countries, following 
both a cross-sectional (2013) and a longitudinal approach (2003-2013) using World 
Bank data. Results: Depending on income strata and LE, countries can expect to 
increase pcHE by 7-10% for an additional LY and between 10-13% for an additional 
QALY. This represent cost per QALY thresholds ranging from 9-11 pcHE in High-
Income to 5-8 in Low-Income countries, which translates to thresholds of 32-40 
thousands US dollars in UK; 83-101 in USA; 6-7 in Mexico and 0.5 in Uganda (around 
0.9, 1.8, 0.6 and 0.7 GDP per capita respectively). cOnclusiOns: This approach, 
based on widely available data, can be useful to inform decisions in all countries 
using economic evaluations. Our results show thresholds usually lower than those 
promoted by WHO.
deaths attributable to AAA in Italy represented 28.0% of the 5EU total, despite 
Italy accounting for only 19.3% of the 5EU population in 2013. cOnclusiOns: Our 
study reveals that the burden of AAA among the 5EU markets is most severe in 
Italy, which accounted for the highest number of both prevalent cases and deaths 
attributable to AAA in the 5EU. Throughout the 5EU, females accounted for a dis-
proportionately high percentage of deaths despite constituting a low percentage 
of prevalent cases. Consequently, current screening guidelines should target both 
sexes, rather than males only.
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Objectives: Published literature suggests that treatment escalation to natali-
zumab, in relapsing-remitting multiple sclerosis (RRMS) patients with inad-
equate response to first-line injectable treatments, is clinically more effective 
than switching among immunomodulators. This analysis evaluates the cost-
effectiveness of escalation vs. switching, adopting the Italian social perspec-
tive. MethOds: A lifetime horizon Markov model compared early escalation to 
natalizumab vs. switching among immunomodulators (interferons or glatiramer 
acetate) followed by escalation to natalizumab, in a cohort of patients who failed 
a first-line therapy. Specifically the two compared treatment algorithms were: 
a) escalation until progression of Expanded Disability Status Scale (EDSS) score 
of 7.0; b) switching until EDSS= 4.0, followed by escalation until EDSS= 7.0. For 
the two options, the model analyzed social costs and quality adjusted survival 
(QALYs). The model captured the effects of therapies in prolonging time without 
disability progression and burden of relapses. Clinical data was derived from a 
published study comparing the two treatment strategies. Unit tariffs and costs 
were adapted to the Italian setting. Results: Early escalation to natalizumab 
was dominant over switching among immunomodulators. The two options led to 
similar costs (€ 1.008 mln/patient in the escalation group, vs. € 1.034 mln/patient 
in the switching group), but early escalation was associated to prolonged qual-
ity adjusted survival (11.54 vs. 9.94 QALYs; +16.05%). A slight overall survival 
increase was also observed (21.14 vs. 20.80 life years). The increased acquisi-
tion costs related to prolonged treatment with natalizumab were offset by sav-
ings due to decreased burden of relapses and a reduction of disability-related 
costs. cOnclusiOns: Early escalation to natalizumab is a cost-effective option 
in RRMS patients who don’t adequately respond to conventional immunomodula-
tors compared to switching among immunomodulators and escalation later. This 
shows that patients benefit from early escalation to natalizumab and prolonging 
immunomodulation, using therapies with similar mechanisms of action, could 
determine inappropriate usage of economic resources and poor benefit for 
patients.
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Objectives: Cardiovascular disease (CVD) risk prediction models are available 
for the general population (Framingham) and for type-2-diabetes (T2D) (UKPDS 
68 and 82) but may not be appropriate in type-1-diabetes (T1D). The IMS CORE 
Diabetes Model (CDM) uses Framingham and UKPDS risk equations (REs) to pre-
dict CVD incidence in T2D and has recently been updated to include two CVD 
risk prediction approaches specific to T1D populations based on data from the 
Epidemiology-of-Diabetes-Interventions-and-Complications-study (EDIC) and 
a novel RE from the Pittsburgh-Epidemiology-of-Diabetes-Complications-Study 
(PEDC). The objective of this study was to compare CVD incidence across T1D 
model projections utilizing UKPDS, EDIC and PEDC REs and compare these to pub-
lished EDIC findings. MethOds: The CDM was applied to project the incidence of 
myocardial-infarction (MI), stroke, heart-failure (HF) and ischemic-heart-disease 
(IHD) utilizing three alternative CVD REs, the UKPDS 68 RE (UK68-RE), EDIC-RE 
and PEDC-RE. The risk profile of a newly diagnosed T1D population (age 21 years, 
HbA1c 7%, systolic-blood-pressure 114 mmHg, body-mass-index 32 Kg/m2, high-
density-lipoprotein 45 mg/dl and total-cholesterol 170 mg/dl) was projected over 
30 years. The incidence of total CVD was estimated as the sum of the individual 
composites (%CVD= %MI+%stroke+IHD+HF) to enable comparison to published 
EDIC findings. Results: When UK68-REs were applied, the 30-year cumulative 
incidence of CVD for a newly diagnosed T1D individual was projected at 2.66%, 
0.27%, 3.88% and 0.72% for MI, stroke, IHD and HF, respectively. This compared to 
4.10%, 0.66%, 3.36 and 0.58% utilizing EDIC-RE and 5.27%, 1.01%, 3.44 and 1.18% 
utilizing PEDC-RE. Total predicted CVD incidence added up to 7.53%, 8.70% and 
10.90% for UK68-RE, EDIC-RE and PEDC-RE respectively, which compares to 8.70% 
incidence of CVD as observed during the EDIC study. cOnclusiOns: As expected, 
the CDM reproduced the published EDIC CVD incidence when using the EDIC 
approach but demonstrated a slight underestimation utilizing UK68-RE and over-
estimation with PEDC-RE.
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